Recently, safety results of NRG-LU004 reported that chemotherapy-free thoracic accelerated fractionated RT (60 Gy/15F) was safe when administered with concurrent durvalumab in LA-NSCLC patients with high PD-L1 expression [119]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.